Correction: Microvascular outcomes after metabolic surgery (MOMS) in patients with type 2 diabetes mellitus and class I obesity: Rationale and design for a randomised controlled trial (BMJ Open (2017) 7 (e013574) DOI: 10.1136/bmjopen-2016-013574);Microvascular Outcomes after Metabolic Surgery (MOMS) in patients with type 2 diabetes mellitus and class I obesity: Rationale and design for a randomised controlled trial

BMJ Open

Volumn 7, Issue 1, 2017, Pages

  Cohen, Ricardo Vitor ^a   Pereira, Tiago Veiga ^a   Aboud, Cristina Mamédio ^a   De Paris Caravatto, Pedro Paulo ^a   Petry, Tarissa Beatrice Zanata ^a   Correa, José Luis Lopes ^a   Schiavon, Carlos Aurélio ^b   Correa, Mariangela ^a   Pompílio, Carlos Eduardo ^a   Pechy, Fernando Nogueira Quirino ^a   Le Roux, Carel ^c  

^a Oswaldo Cruz German Hospital   (Brazil)

^b Heart Hospital   (Brazil)

^c UNIVERSITY COLLEGE DUBLIN   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIDIABETIC AGENT; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN; INSULIN; LOW DENSITY LIPOPROTEIN; METFORMIN; SIMVASTATIN; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; BEST MEDICAL TREATMENT; BODY MASS; CLASS 1 OBESITY; CLINICAL EFFECTIVENESS; COMORBIDITY; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; CREATININE URINE LEVEL; DIABETIC NEUROPATHY; DIABETIC RETINOPATHY; ELASTOGRAPHY; FOLLOW UP; GLYCEMIC CONTROL; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; LIVER BIOPSY; MAJOR CLINICAL STUDY; MICROVASCULARIZATION; NON INSULIN DEPENDENT DIABETES MELLITUS; NUTRITIONAL ASSESSMENT; OBESITY; OUTCOME ASSESSMENT; PATIENT SAFETY; PHARMACEUTICAL CARE; PHASE 3 CLINICAL TRIAL; PHYSICAL ACTIVITY; RANDOMIZED CONTROLLED TRIAL; REMISSION; ROUX-EN-Y GASTRIC BYPASS; STUDY DESIGN; URINE SAMPLING; COMPLICATION; DIABETIC ANGIOPATHY; FEMALE; GASTRIC BYPASS SURGERY; MALE; MORBID OBESITY; PATHOPHYSIOLOGY; TREATMENT OUTCOME;

ADULT; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; FEMALE; FOLLOW-UP STUDIES; GASTRIC BYPASS; HUMANS; MALE; OBESITY, MORBID; TREATMENT OUTCOME;

EID: 85009471232     PISSN: None     EISSN: 20446055     Source Type: Journal    
DOI: 10.1136/bmjopen-2016-013574corr1     Document Type: Erratum

References (32)

1. Schauer PR, Bhatt DL, Kirwan JP, et al. Bariatric surgery versus intensive medical therapy for diabetes-3-year outcomes. N Engl J Med 2014;370: 2002-13.
2. Schauer PR, Kashyap SR, Wolski K, et al. Bariatric surgery versus intensive medical therapy in obese patients with diabetes. N Engl J Med 2012;366: 1567-76.
3. Ikramuddin S, Korner J, Lee W-J, et al. Roux-en-Y gastric bypass vs intensive medical management for the control of type 2 diabetes, hypertension, and hyperlipidemia: The diabetes surgery study randomized clinical trial Roux-en-Y gastric bypass and diabetes. JAMA 2013;309: 2240-9.
4. Ikramuddin S, Billington CJ, Lee WJ, et al. Roux-en-Y gastric bypass for diabetes (the Diabetes Surgery Study): 2-year outcomes of a 5-year, randomised, controlled trial. Lancet Diabetes Endocrinol 2015;3: 413-22.
5. Mingrone G, Panunzi S, De Gaetano A, et al. Bariatric-metabolic surgery versus conventional medical treatment in obese patients with type 2 diabetes: 5 year follow-up of an open-label, single-centre randomised controlled trial. Lancet 2015;386: 964-73.
6. Mingrone G, Panunzi S, De Gaetano A, et al. Bariatric surgery versus conventional medical therapy for type 2 diabetes. N Engl J Med 2012;366: 1577-85.
7. Gloy VL, Briel M, Bhatt DL, et al. Bariatric surgery versus non-surgical treatment for obesity: A systematic review and meta-Analysis of randomised controlled trials. BMJ 2013;347: F5934.
8. Sjöholm K, Anveden Å, Peltonen M, et al. Evaluation of current eligibility criteria for bariatric surgery: Diabetes prevention and risk factor changes in the Swedish Obese Subjects (SOS) study. Diabetes Care 2013;36: 1335-40.
9. Sjöström L, Peltonen M, Jacobson P, et al. Association of bariatric surgery with long-Term remission of type 2 diabetes and with microvascular and macrovascular complications. JAMA 2014;311: 2297.
10. Ferrannini E, Mingrone G. Impact of different bariatric surgical procedures on insulin action and cell beta-cell function in type 2 diabetes. Diabetes Care 2009;32: 514-20.
11. Sjöström L, Peltonen M, Jacobson P, et al. Bariatric surgery and long-Term cardiovascular events. JAMA 2012;307: 56-65.
12. Romeo S, Maglio C, Burza MA, et al. Cardiovascular events after bariatric surgery in obese subjects with type 2 diabetes. Diabetes Care 2012;35: 2613-17.
13. Adams TD, Gress RE, Smith SC, et al. Long-Term mortality after gastric bypass surgery. N Engl J Med 2007;357: 753-61.
14. Adams TD, Davidson LE, Litwin SE, et al. Health benefits of gastric bypass surgery after 6 years. JAMA 2012;308: 1122-31.
15. Adams TD, Pendleton RC, Strong MB, et al. Health outcomes of gastric bypass patients compared to nonsurgical, nonintervened severely obese. Obesity (Silver Spring) 2010;18: 121-30.
16. Rubino F, Amiel SA. Is the gut the "Sweet Spot" for the treatment of diabetes? Diabetes 2014;63: 2225-8.
17. Pories WJ, Dohm LG, Mansfield CJ. Beyond the BMI: The search for better guidelines for bariatric surgery. Obesity (Silver Spring) 2010;18: 865-71.
18. le Roux CW, Aylwin SJB, Batterham RL, et al. Gut hormone profiles following bariatric surgery favor an anorectic state, facilitate weight loss, and improve metabolic parameters. Ann Surg 2006;243: 108.
19. Cummings DE, Cohen RV. Beyond BMI: The need for new guidelines governing the use of bariatric and metabolic surgery. Lancet Diabetes Endocrinol 2014;2: 175-81.
20. Cohen R. Bariatric surgery: Time to move beyond clinical outcomes. Lancet Diabetes Endocrinol 2015;3: 829-31.
21. Sharma AM, Kushner RF. A proposed clinical staging system for obesity. Int J Obes 2009;33: 289-95.
22. DeFronzo RA, Ferrannini E. Insulin resistance: A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care 1991;14: 173-94.
23. Knowler WC, Fowler SE, Hamman RF, Diabetes Prevention Program Research Group. 10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet 2009;374: 1677-86.
24. American Diabetes Association. Standards of medical care in diabetes-2013. Diabetes Care 2013;36(Suppl 1): S11-66.
25. Afkarian M, Sachs MC, Kestenbaum B, et al. Kidney disease and increased mortality risk in type 2 diabetes. J Am Soc Nephrol 2013;24: 302-8.
26. Gallagher H, Suckling RJ. Diabetic nephropathy-where are we on the journey from pathophysiology to treatment? Diabetes Obes Metab 2016;18: 641-7.
27. Chen Y, Corsino L, Shantavasinkul PC, et al. Gastric bypass surgery leads to long-Term remission or improvement of type 2 diabetes and significant decrease of microvascular and macrovascular complications. Ann Surg 2016;263: 1138-42.
28. Upala S, Wijarnpreecha K, Congrete S, et al. Bariatric surgery reduces urinary albumin excretion in diabetic nephropathy-A systematic review and meta-Analysis. Surg Obes Relat Dis 2016;12: 1037-44.
29. Schauer PR, Burguera B, Ikramuddin S, et al. Effect of laparoscopic Roux-en Y gastric bypass on type 2 diabetes mellitus. Ann Surg 2003;238: 467-84.
30. Cohen RV, Pinheiro JC, Schiavon CA, et al. Effects of gastric bypass surgery in patients with type 2 diabetes and only mild obesity. Diabetes Care 2012;35: 1420-8.
31. Cummings DE, Cohen RV. Bariatric/metabolic surgery to treat type 2 diabetes in patients with a BMI35 kg/m 2 Diabetes Care 2016 39 924-33.
32. White IR, Horton NJ, Carpenter J, et al. Strategy for intention to treat analysis in randomised trials with missing outcome data. BMJ 2011;342: D40.